Psoriatic Disease

Ixekizumab demonstrates a safety and tolerability profile that is “reassuring” and consistent with previous studies in patients with psoriatic arthritis, according to researchers.

A “large proportion” of patients with psoriatic arthritis fail to reach treatment targets despite medication, with residual musculoskeletal and skin disease frequently observed, according to data published in Rheumatology and Therapy.

The presence of cardiac troponin I may indicate a risk for atherosclerosis in patients with psoriatic disease independently from traditional cardiovascular risk factors, according to data published in Arthritis and Rheumatology.

The National Psoriasis Foundation COVID-19 Task Force has updated its guidelines to recommend a second booster shot for some patients with psoriasis or psoriatic arthritis.

Deucravacitinib, a TYK2 inhibitor, was well-tolerated and superior to placebo in improving ACR20 response among patients with psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.

The Congress of Clinical Rheumatology-East is back for 2022 as it was in 2021: On-site and online.

Secukinumab provides early, clinically meaningful, statistically significant and sustained improvements in patient-reported outcomes across all doses, compared with placebo, in active psoriatic arthritis, according to data.

Cardiovascular screening and management programs led by dermatology providers for patients with psoriasis may fill gaps left in the absence of primary care, according to survey findings that included both dermatologists and patients.

WAIKOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2022, Laura M. Periman, MD, discusses a case of dupilumab-induced ocular surface disease and management strategies.

Approximately 61% of patients with rheumatoid arthritis or psoriatic arthritis who use methotrexate report side effects following weekly dosing, including fatigue and nausea, according to data published in Rheumatology and Therapy.